Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
about
Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Efficacy and safety of ixekizu ...... ed, phase 3 study (UNCOVER-1).
@en
type
label
Efficacy and safety of ixekizu ...... ed, phase 3 study (UNCOVER-1).
@en
prefLabel
Efficacy and safety of ixekizu ...... ed, phase 3 study (UNCOVER-1).
@en
P2093
P2860
P356
P1476
Efficacy and safety of ixekizu ...... ed, phase 3 study (UNCOVER-1).
@en
P2093
Atsushi Nishikawa
Fangyi Zhao
Gregory S Cameron
Japanese UNCOVER-1 Study Group
P2860
P304
P356
10.1111/1346-8138.13927
P577
2017-06-21T00:00:00Z